Pharvaris (NASDAQ:PHVS) Reaches New 1-Year High - Here's What Happened

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report)'s share price hit a new 52-week high on Saturday . The company traded as high as $25.76 and last traded at $25.12, with a volume of 155746 shares changing hands. The stock had previously closed at $19.83.

Analyst Upgrades and Downgrades

PHVS has been the subject of a number of research reports. Wedbush reaffirmed an "outperform" rating and set a $27.00 target price on shares of Pharvaris in a report on Thursday, June 5th. Guggenheim started coverage on Pharvaris in a research note on Wednesday, June 11th. They issued a "buy" rating and a $32.00 price objective for the company. Finally, Cantor Fitzgerald decreased their target price on Pharvaris from $28.00 to $25.00 and set an "overweight" rating on the stock in a report on Wednesday, May 14th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Pharvaris presently has an average rating of "Buy" and an average price target of $36.20.

Pharvaris Stock Performance

The stock has a market cap of $1.31 billion, a P/E ratio of -8.35 and a beta of -2.82. The stock's fifty day moving average is $17.26 and its 200 day moving average is $16.71.

Pharvaris (NASDAQ:PHVS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.09). Equities research analysts predict that Pharvaris N.V. will post -2.71 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in PHVS. JPMorgan Chase & Co. increased its stake in Pharvaris by 1,125.3% in the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock worth $59,000 after buying an additional 2,847 shares during the period. Cubist Systematic Strategies LLC purchased a new position in Pharvaris in the 4th quarter worth about $64,000. KLP Kapitalforvaltning AS purchased a new position in Pharvaris in the 4th quarter worth about $111,000. Point72 Asset Management L.P. purchased a new position in Pharvaris in the 4th quarter worth about $152,000. Finally, Legal & General Group Plc increased its stake in Pharvaris by 11.2% in the 4th quarter. Legal & General Group Plc now owns 9,855 shares of the company's stock worth $189,000 after buying an additional 994 shares during the period.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.